As Dr T has pointed out, when comparing bisantrene with other FTO inhibitors, the clinical history or lack thereof is more important than the precise amount by which bisantrene is more potent than its "peers".
I think it's sufficient to say in the "bisantrene among peers" section that bisantrene ticks both boxes, and that brequinar has unpredictable dosing and dangerous auto immune side effects.
- Forums
- ASX - By Stock
- RAC
- RAC Primer
RAC Primer, page-164
-
-
- There are more pages in this discussion • 358 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.79 |
Change
0.005(0.28%) |
Mkt cap ! $305.0M |
Open | High | Low | Value | Volume |
$1.80 | $1.84 | $1.79 | $124.5K | 68.54K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 1427 | $1.79 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.80 | 2279 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 1427 | 1.785 |
3 | 15400 | 1.780 |
1 | 1690 | 1.775 |
1 | 11200 | 1.770 |
1 | 2200 | 1.760 |
Price($) | Vol. | No. |
---|---|---|
1.790 | 2200 | 1 |
1.800 | 2279 | 1 |
1.805 | 800 | 1 |
1.810 | 3564 | 1 |
1.815 | 4294 | 1 |
Last trade - 15.00pm 01/10/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
TON
TRITON MINERALS LTD
Adrian Costello, Executive Director
Adrian Costello
Executive Director
Previous Video
Next Video
SPONSORED BY The Market Online